Experts on the panel shared many of the same views around SSRIs, arguing the risks of the drugs during pregnancy are greater ...

An unusual FDA panel on antidepressant use during pregnancy elevated clinicians and researchers who are deeply skeptical of ...

A Food and Drug Administration panel discussing the use of antidepressants during pregnancy Monday largely amounted to ...

The Food and Drug Administration is considering adding warning labels to antidepressants for women who are pregnant, despite ...

At a recent FDA panel on SSRIs in pregnancy, the chair suggested rising antidepressant use may be contributing to — not easing — the nation’s depression rates.

When the U.S. Food and Drug Administration (FDA) convened a public expert panel to review the use of selective serotonin ...

Members of an advisory panel have proposed adding warning labels to some medication about adverse maternal and fetal risks in ...

Members of an FDA expert panel discussed the risks and benefits of selective serotonin reuptake inhibitors, or SSRIs, for ...

Currently, there's only one drug on the market that's FDA-approved to treat postpartum depression. The drug, called Zulresso, is only available through 60-hour, one-time infusion, and can cost as ...

August 24, 2010 — A new review of 4 meta-analyses of efficacy trials submitted to the US Food and Drug Administration (FDA) suggests that antidepressants are only "marginally efficacious" compared ...